Publications by authors named "Angelo Ghezzi"

Claim this Profile
A
A narrative review of genetic and environmental factors and risk for multiple sclerosis. The design of the Italian multicentric PEDIGREE study.
Angelo Ghezzi, Sandra D'Alfonso, Maura Pugliatti, Silvy Pilotto, Martina Tosi

Neurol Sci· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pediatric, adult, and late onset multiple sclerosis: Cognitive phenotypes and gray matter atrophy.
Ermelinda De Meo, Emilio Portaccio, Rosa Cortese, Luis Ruano, Benedetta Goretti, Angelo Ghezzi

Ann Clin Transl Neurol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Old and New Strategies in the Treatment of Pediatric Multiple Sclerosis: A Personal View for a New Treatment Approach.
Angelo Ghezzi

Neurol Ther· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Neurofilament Light Chain in Adult and Pediatric Multiple Sclerosis: A Promising Biomarker to Better Characterize Disease Activity and Personalize MS Treatment.
Angelo Ghezzi, R F Neuteboom

Neurol Ther· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neurofilament Light Chain in Adult and Pediatric Multiple Sclerosis: A Promising Biomarker to Better Characterize Disease Activity and Personalize MS Treatment.
Angelo Ghezzi, R F Neuteboom

Neurol Ther· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The contribution of neurofilament light chain to better characterize pediatric multiple sclerosis (editorial on: Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial).
Angelo Ghezzi, Rinze F Neuteboom

Mult Scler· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6 years.
Emilio Portaccio, Luisa Pastò, Lorenzo Razzolini, Lucia Moiola, Vittorio Martinelli, Angelo Ghezzi

Mult Scler· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study.
Damiano Baroncini, Angelo Ghezzi, Clara Guaschino, Lucia Moiola, Massimo Filippi

Neurol Sci· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset.
Emilio Portaccio, Angelo Bellinvia, Lorenzo Razzolini, Luisa Pastò, Benedetta Goretti, Angelo Ghezzi

Neurology· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening.
Emilio Portaccio, Laura Tudisco, Luisa Pastò, Lorenzo Razzolini, Mattia Fonderico, Angelo Ghezzi

Mult Scler· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of fingolimod on health-related quality of life in paediatric patients with multiple sclerosis: results from the phase 3 PARADIG Study.
Lauren Krupp, Brenda Banwell, Tanuja Chitnis, Kumaran Deiva, Jutta Gaertner, Angelo Ghezzi

BMJ Neurol Open· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations.
Angelo Ghezzi, Brenda Banwell, Amit Bar-Or, Tanuja Chitnis, Russell C Dale

Mult Scler· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Etiological research in pediatric multiple sclerosis: A tool to assess environmental exposures (PEDiatric Italian Genetic and enviRonment ExposurE Questionnaire).
Silvy Pilotto, Jessica Gencarelli, Stefania Bova, Leonardo Gerosa, Damiano Baroncini, Angelo Ghezzi

Mult Scler J Exp Transl Clin· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis.
Damiano Baroncini, Marta Simone, Pietro Iaffaldano, Vincenzo Brescia Morra, Roberta Lanzillo, Angelo Ghezzi

JAMA Neurol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIG study.
Tanuja Chitnis, Brenda Banwell, Lauren Krupp, Douglas L Arnold, Amit Bar-Or, Angelo Ghezzi

Mult Scler· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying the Distinct Cognitive Phenotypes in Multiple Sclerosis.
Ermelinda De Meo, Emilio Portaccio, Antonio Giorgio, Luis Ruano, Benedetta Goretti, Angelo Ghezzi

JAMA Neurol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges.
Angelo Ghezzi, Maria Pia Amato, Gilles Edan, Hans-Peter Hartung, Eva Kubala Havrdová

Mult Scler· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo gradients of thalamic damage in paediatric multiple sclerosis: a window into pathology.
Ermelinda De Meo, Loredana Storelli, Lucia Moiola, Angelo Ghezzi, Pierangelo Veggiotti

Brain· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis.
Maria Pia Amato, Mattia Fonderico, Emilio Portaccio, Luisa Pastò, Lorenzo Razzolini, Angelo Ghezzi

Brain· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Long-Term Effect of Immediate Versus Delayed Fingolimod Treatment in Young Adult Patients with Relapsing-Remitting Multiple Sclerosis: Pooled Analysis from the FREEDOMS/FREEDOMSII Trials.
Angelo Ghezzi, Tanuja Chitnis, Annik K-Laflamme, Rolf Meinert, Dieter A Häring

Neurol Ther· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIG study.
Douglas L Arnold, Brenda Banwell, Amit Bar-Or, Angelo Ghezzi, Benjamin M Greenberg

J Neurol Neurosurg Psychiatry· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Aging with multiple sclerosis: prevalence and profile of cognitive impairment.
Mariana Branco, Luis Ruano, Emilio Portaccio, Benedetta Goretti, Claudia Niccolai, Angelo Ghezzi

Neurol Sci· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Effect of Immediate Versus Delayed Fingolimod Treatment in Young Adult Patients with Relapsing-Remitting Multiple Sclerosis: Pooled Analysis from the FREEDOMS/FREEDOMS II Trials.
Angelo Ghezzi, Tanuja Chitnis, Annik K-Laflamme, Rolf Meinert, Dieter A Häring

Neurol Ther· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS.
Angelo Ghezzi, Giancarlo Comi, Luigi Maria Grimaldi, Lucia Moiola, Carlo Pozzilli

Neurol Neuroimmunol Neuroinflamm· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Different MRI patterns in MS worsening after stopping fingolimod.
Caterina Lapucci, Damiano Baroncini, Maria Cellerino, Giacomo Boffa, Ilaria Callegari, Angelo Ghezzi

Neurol Neuroimmunol Neuroinflamm· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis